SEPS Pharma is a privately held pharmaceutical company engaged in drug delivery and development. The company is established as a spin-off project from the Biomedical Research Institute, Hasselt University, with headquarters in Tongeren, Belgium. SEPS Pharma applies the combination of carefully designed prodrugs with the appropriate delivery forms creating innovative therapies for patients by expanding the medical application field of existing and well-characterised drugs, initially targeted to the following therapeutic areas: infectious diseases (antiviral, antifungal, antibacterial), oncology, migraine, chemotherapy-induced and postoperative nausea vomiting. The edge of the company resides in the fact that SEPS Pharma is developing and possibly relaunch variants of highly selling drugs, including blockbusters, for a second 'patent life protected' period with substantial improvements over the initial parent drug.